Advantage Alpha Capital Partners LP Grows Stock Holdings in Enovis Co. (NYSE:ENOV)

Advantage Alpha Capital Partners LP increased its stake in Enovis Co. (NYSE:ENOV) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 90,972 shares of the company’s stock after buying an additional 3,017 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Enovis were worth $3,992,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. increased its holdings in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after purchasing an additional 300 shares during the last quarter. FMR LLC increased its stake in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. XTX Topco Ltd purchased a new position in Enovis in the third quarter worth about $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new position in shares of Enovis in the fourth quarter worth approximately $228,000. Institutional investors own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reduced their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

Enovis Stock Performance

Shares of ENOV stock opened at $39.12 on Monday. The firm has a market capitalization of $2.23 billion, a PE ratio of -17.86 and a beta of 2.05. The company has a 50 day moving average price of $42.72 and a 200-day moving average price of $43.50. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. As a group, equities research analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.